|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||76.01 - 76.71|
|52 Week Range||48.52 - 89.78|
|Beta (3Y Monthly)||0.74|
|PE Ratio (TTM)||36.68|
|Forward Dividend & Yield||1.47 (1.95%)|
|1y Target Est||90.48|
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 4) Agile Therapeutics Inc (NASDAQ: AGRX )(follow-on rally ...
Shares in Eisai Co , Biogen's Japanese partner in the drug, were quoted up 18% to the daily limit high of 6,534 yen in Tokyo trading. The field of experimental Alzheimer's treatments is littered with high-profile failures, with many major drugmakers abandoning the race to develop a medicine for a disease that makes up 60%-70% of an estimated 50 million dementia cases globally. Any medicine that effectively treats the disease is likely to become one of the world's top-selling drugs and could be transformative for Biogen, which is facing multiple challenges over its product pipeline.
The stock fell under the psychological barrier of $300 March 21, when the company and its development partner Eisai Co., Ltd (OTC: ESALY) announced their decision to shelve two late-stage studies dubbed ENGAGE and EMERGE that evaluated the efficacy and safety of aducanumab in patients with mild cognitive impairment due to Alzheimer's disease and mild Alzheimer's disease dementia. Biogen said Tuesday it plans to file a BLA for aducanumab for the treatment of early Alzheimer's disease following consultation with the FDA.
Biogen said it will pursue regulatory approval for aducanumab, an investigational treatment for early Alzheimer's disease after consulting with the U.S. Food and Drug Administration. A Phase 3 trial met its primary endpoint showing a significant reduction in clinical decline, and Biogen believes that results from a subset of patients in the study who received sufficient exposure to high dose aducanumab support the finding. The decision to file is based on a new analysis, conducted by Biogen in consultation with the FDA, of a larger dataset from the Phase 3 clinical studies that were discontinued in March 2019 following a futility analysis.
The U.S., Australia, and Canada will allow Merck’s Keytruda to be used together with a drug developed by Japan’s Eisai to treat some forms of advanced endometrial carcinoma.
Biogen stock popped in relief Friday after the biotech company scrapped several tests in Alzheimer's treatment for a drug known as elenbecestat. It was being developed with Japan's Eisai.
Biogen Inc and Eisai Co Ltd are abandoning two late-stage trials for their Alzheimer's treatment in a widely anticipated move that comes months after the companies scrapped trials of another drug for the memory-robbing disease. The companies said on Friday the decision was based on the results of a review conducted by a data safety monitoring board, which recommended discontinuing the trials as benefits from the treatment, elenbecestat, did not outweigh its risks. Shares of Biogen were up 2.3% at $237.60 as some analysts said ending the trial would save the company costs associated with running it through its completion.
Shares of Biogen Inc. fell 1.6% in premarket trading Friday, after the the biotechnology company and Tokyo-based Eisai Co. Ltd. said they will discontinue the phase 3 trial of an Alzheimer's disease (AD) treatment, citing data showing an unfavorable risk-benefit ratio. The decision was made after the Data Safety Monitoring Board's recommendation to discontinue the trials. The trial on the investigational oral beta amyloid cleaving enyzme (BACE) inhibitor elenbecestat in patients with early AD. The companies said as part of the decision to discontinue the phase 3 trial, the long-term extension of the phase 2 trial of elenbecestat will also be discontinued. Biogen's stock has dropped 22.8% year to date through Thursday and the U.S.-listed shares of Eisai have tumbled 34.6%, while the S&P 500 has gained 20.1%.
Japanese drug maker Eisai Co., Ltd (OTC: ESALY ) has some positive news concerning one of its pipeline candidates. What Happened Eisai said the FDA has granted Breakthrough Therapy Designation for Lenvima, ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 22) Acasti Pharma Inc (NASDAQ: ACST ) Apellis Pharmaceuticals ...
Investors should keep tabs on these "focus events" from this quartet of U.S.-listed Japanese drugmakers that can make or break their treatments.
Alzheimer's treatment continues to confound biotech companies in the wake of Biogen and Eisai's decision to terminate two late-stage tests. But scientists say there's hope in new theories.
Ocular's (OCUL) phase III study on OTX-TP for the reduction of intraocular pressure (IOP) in patients with primary open-angle glaucoma fails to achieve primary endpoint.
Comparing MRK’s and ABBV’s Outlook: Which Is the Better Pick?(Continued from Prior Part)Lenvima growth trendsIn the first quarter, Merck’s (MRK) and Eisai’s Lenvima reported solid uptake across multiple markets, driven mainly by demand in
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 30) VolitionRX Ltd (NYSE: VNRX ) ZEALAND PHARMA/S ADR ...